Action TARS TARSUS PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Tarsus Pharmaceuticals, Inc.

Actions

TARS

US87650L1035

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 15/05/2024 		Varia. 5j. Varia. 1 janv.
38,5 USD +1,34% Graphique intraday de Tarsus Pharmaceuticals, Inc. +3,08% +90,12%
09/05 TARSUS PHARMACEUTICALS, INC. : Oppenheimer reste à l'achat ZM
08/05 Transcript : Tarsus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
Tarsus Pharmaceuticals : Corporate Presentation
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q1 Revenue $27.6M, vs. Street Est of $17.9M
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Tarsus Pharmaceuticals, Inc. Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-Dilutive Financing Commitment from Pharmakon
Tarsus Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc
Tarsus Pharmaceuticals : Corporate Presentation
Tarsus to Participate at Upcoming Investor Conferences
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
Tarsus Pharmaceuticals Prices $100 Million Public Offering
Tarsus Announces Pricing of $100.0 Million Public Offering
Tarsus Announces Proposed $100.0 Million Public Offering
Tarsus Pharmaceuticals' Q4 Net Loss Widens, Revenue Increases
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TARS
  4. Actualités Tarsus Pharmaceuticals, Inc.
  5. Autres langues